Patents by Inventor Michelle E. Pizzo

Michelle E. Pizzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HER2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20260109781
    Abstract: In one aspect, antibodies that bind to subdomain II of human HER2 are provided. In another aspect, antibodies comprising a light chain polypeptide that pairs with both a heavy chain polypeptide for binding to subdomain II of human HER2 and a heavy chain polypeptide for binding to subdomain IV of human HER2 are provided. In a further aspect, antibodies that bind to both subdomain II and subdomain IV of human HER2 comprising a common light chain polypeptide are provided. Methods of treating a cancer or treating brain metastasis of a cancer using these antibodies are also provided.
    Type: Application
    Filed: October 8, 2025
    Publication date: April 23, 2026
    Inventors: Abira BANDYOPADHYAY, Allisa Jayne CLEMENS, Do Jin KIM, Michelle E. PIZZO, Lu SHAN, Richard THÉOLIS, Jr., Raymond Ka Hang TONG
  • ANTI-HER2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20250136713
    Abstract: In one aspect, antibodies that bind to subdomain II of human HER2 are provided. In another aspect, antibodies comprising a light chain polypeptide that pairs with both a heavy chain polypeptide for binding to subdomain II of human HER2 and a heavy chain polypeptide for binding to subdomain IV of human HER2 are provided. In a further aspect, antibodies that bind to both subdomain II and subdomain IV of human HER2 comprising a common light chain polypeptide are provided. Methods of treating a cancer or treating brain metastasis of a cancer using these antibodies are also provided.
    Type: Application
    Filed: August 25, 2022
    Publication date: May 1, 2025
    Inventors: Abira BANDYOPADHYAY, Allisa Jayne CLEMENS, Do Jin KIM, Michelle E. PIZZO, Lu SHAN, Richard THÉOLIS, Jr., Raymond Ka Hang TONG
  • ENGINEERED ANTI-HER2 BISPECIFIC PROTEINS
    Publication number: 20240392035
    Abstract: In one aspect, bispecific proteins having the ability to specifically bind to both subdomain II of human HER2 and subdomain IV of human HER2 are provided. In another aspect, methods of treating a cancer or treating brain metastasis of a cancer using a bispecific protein that specifically binds to subdomain II and subdomain IV of human HER2 are provided.
    Type: Application
    Filed: August 25, 2022
    Publication date: November 28, 2024
    Inventors: Abira BANDYOPADHYAY, Allisa Jayne CLEMENS, Do Jin KIM, Michelle E. PIZZO, Lu SHAN, Richard THÉOLIS, Jr., Raymond Ka Hang TONG
  • Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
    Patent number: 10123969
    Abstract: A method of enhancing therapeutic/drug transport to the perivascular space of the brain of a patient is disclosed. In one embodiment, the method comprises the step of introducing a therapeutic/drug and an osmolyte of the present invention into a patient's cerebrospinal fluid (CSF), wherein the osmolyte is introduced to the CSF at a concentration of between 0.5 and 12.9 M (dependent on the solubility upper limit of the osmolyte), and wherein the therapeutic/drug delivery to the perivascular spaces of cerebral blood vessels and parenchyma of the central nervous system is facilitated by the presence of the osmolyte.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: November 13, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Robert G. Thorne, Michelle E. Pizzo, Daniel J. Wolak
  • OSMOTIC ENHANCEMENT OF DRUG/THERAPEUTIC DELIVERY TO THE BRAIN FOLLOWING INFUSION OR INJECTION INTO THE CEREBROSPINAL FLUID
    Publication number: 20170105927
    Abstract: A method of enhancing therapeutic/drug transport to the perivascular space of the brain of a patient is disclosed. In one embodiment, the method comprises the step of introducing a therapeutic/drug and an osmolyte of the present invention into a patient's cerebrospinal fluid (CSF), wherein the osmolyte is introduced to the CSF at a concentration of between 0.5 and 12.9 M (dependent on the solubility upper limit of the osmolyte), and wherein the therapeutic/drug delivery to the perivascular spaces of cerebral blood vessels and parenchyma of the central nervous system is facilitated by the presence of the osmolyte.
    Type: Application
    Filed: October 14, 2016
    Publication date: April 20, 2017
    Inventors: Robert G. Thorne, Michelle E. Pizzo, Daniel J. Wolak